tbuckley/cabot-search huggingface dataset:
Mechanosensation of the heart and gut elicits hypometabolism and vigilance in mice
Authors: Karen A. Scott, Yalun Tan, Dominique N. Johnson, Khalid Elsaafien, Caitlin Baumer-Harrison, Rebeca Méndez-Hernández, Matthew K. Kirchner, Sophia A. Eikenberry, Jessica M. Sa, Javier E. Stern, Guillaume de Lartigue, Annette D. de Kloet, Eric G. Krause
Journal: Nature Metabolism (2025)
Data sharing restrictions are hampering precision health in the European Union
Authors: Cristina Legido-Quigley, Nicolai J. Wewer Albrechtsen, Martin Bæk Blond, Marcelo Corrales Compagnucci, Madeleine Ernst, Markus J. Herrgård, Timo Minssen, Filip Ottosson, Flemming Pociot, Peter Rossing, Karolina Sulek
Journal: Nature Medicine (2025)
Dynamical constraints on neural population activity
Authors: Emily R. Oby, Alan D. Degenhart, Erinn M. Grigsby, Asma Motiwala, Nicole T. McClain, Patrick J. Marino, Byron M. Yu, Aaron P. Batista
Journal: Nature Neuroscience (2025)

The manner in which neural activity unfolds over time is thought to be central to sensory, motor and cognitive functions in the brain. Network models have long posited that the brain's computations involve time courses of activity that are shaped by the underlying network. A prediction from this view is that the activity time courses should be difficult to violate. We leveraged a brain-computer interface to challenge monkeys to violate the naturally occurring time courses of neural population activity that we observed in the motor cortex. This included challenging animals to traverse the natural time course of neural activity in a time-reversed manner. Animals were unable to violate the natural time courses of neural activity when directly challenged to do so. These results provide empirical support for the view that activity time courses observed in the brain indeed reflect the underlying network-level computational mechanisms that they are believed to implement.
Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington’s disease decades before clinical motor diagnosis
Authors: Rachael I. Scahill, Mena Farag, Michael J. Murphy, Nicola Z. Hobbs, Michela Leocadi, Christelle Langley, Harry Knights, Marc Ciosi, Kate Fayer, Mitsuko Nakajima, Olivia Thackeray, Johan Gobom, John Rönnholm, Sophia Weiner, Yara R. Hassan, Nehaa K. P. Ponraj, Carlos Estevez-Fraga, Christopher S. Parker, Ian B. Malone, Harpreet Hyare, Jeffrey D. Long, Amanda Heslegrave, Cristina Sampaio, Hui Zhang, Trevor W. Robbins, Henrik Zetterberg, Edward J. Wild, Geraint Rees, James B. Rowe, Barbara J. Sahakian, Darren G. Monckton, Douglas R. Langbehn, Sarah J. Tabrizi
Journal: Nature Medicine (2025)
Propagation of neuronal micronuclei regulates microglial characteristics
Authors: Sarasa Yano, Natsu Asami, Yusuke Kishi, Ikuko Takeda, Hikari Kubotani, Yuki Hattori, Ayako Kitazawa, Kanehiro Hayashi, Ken-ichiro Kubo, Mai Saeki, Chihiro Maeda, Chihiro Hiraki, Rin-ichiro Teruya, Takumi Taketomi, Kaito Akiyama, Tomomi Okajima-Takahashi, Ban Sato, Hiroaki Wake, Yukiko Gotoh, Kazunori Nakajima, Takeshi Ichinohe, Takeshi Nagata, Tomoki Chiba, Fuminori Tsuruta
Journal: Nature Neuroscience (2025)
Ferroptosis and pyroptosis are connected through autophagy: a new perspective of overcoming drug resistance
Authors: Peng Zhao, Shuangshuang Yin, Yuling Qiu, Changgang Sun, Haiyang Yu
Journal: Molecular Cancer (2025)

Drug resistance is a common challenge in clinical tumor treatment. A reduction in drug sensitivity of tumor cells is often accompanied by an increase in autophagy levels, leading to autophagy-related resistance. The effectiveness of combining chemotherapy drugs with autophagy inducers/inhibitors has been widely confirmed, but the mechanisms are still unclear. Ferroptosis and pyroptosis can be affected by various types of autophagy. Therefore, ferroptosis and pyroptosis have crosstalk via autophagy, potentially leading to a switch in cell death types under certain conditions. As two forms of inflammatory programmed cell death, ferroptosis and pyroptosis have different effects on inflammation, and the cGAS-STING signaling pathway is also involved. Therefore, it also plays an important role in the progression of some chronic inflammatory diseases. This review discusses the relationship between autophagy, ferroptosis and pyroptosis, and attempts to uncover the reasons behind the evasion of tumor cell death and the nature of drug resistance.
Current and novel biomarkers in cardiogenic shock
Authors: Victor Galusko, Florian A. Wenzl, Christophe Vandenbriele, Vasileios Panoulas, Thomas F. Lüscher, Diana A. Gorog
Journal: European Journal of Heart Failure (2025)

Abstract Cardiogenic shock (CS) carries a 30–50% in‐hospital mortality rate, with little improvement in outcomes in the last decade. Challenges in improving outcomes are closely linked to the frequent late presentation or diagnosis of CS where the ‘point of no return’ has often passed, leading to haemodynamic dysregulation, progressive myocardial depression, hypotension, and a downward spiral of hypoperfusion, organ dysfunction and decreasing myocardial function, driven by inflammation and metabolic derangements. Novel therapeutic interventions may have varying efficacy depending on the type and stage of shock in which they are applied. Biomarkers that aid prediction and early detection of CS, provide early signs of organ dysfunction and define prognosis could help optimize management. Temporal change in such biomarkers, particularly in response to pharmacological interventions and/or mechanical circulatory support, can guide management and predict outcome. Several novel biomarkers enhance the prediction of mortality in CS, compared to conventional parameters such as lactate, with some, such as adrenomedullin and circulating dipeptidyl peptidase 3, also able to predict the development of CS. Some biomarkers reflect systemic inflammation (e.g. interleukin‐6, angiopoietin 2, fibroblast growth factor 23 and suppressor of tumorigenicity 2) and are not specific to CS, yet inform on the activation of important pathways involved in the downward shock spiral. Other biomarkers signal end‐organ hypoperfusion and could guide targeted interventions, while some may serve as novel therapeutic targets. We critically review current and novel biomarkers that guide prediction, detection, and prognostication in CS. Future use of biomarkers may help improve management in these high‐risk patients.
The FBXO45-GEF-H1 axis controls germinal center formation and B-cell lymphomagenesis
Authors: Anagh A. Sahasrabuddhe, Xiaofei Chen, Kaiyu Ma, Rui Wu, Huan-Chang Liang, Richa Kapoor, Rishi R. Chhipa, Ozlem Onder, Courtney McFetridge, John S. Van Arnam, Xiao Zhang, Jennifer J.D. Morrissette, Vinodh Pillai, Marilyn M. Li, Philippe Szankasi, Venkatesha Basrur, Kevin P. Conlon, Tobias D. Raabe, Nathanael G. Bailey, Cory M. Hogaboam, Robert Rottapel, Junhyong Kim, Cristina López, Matthias Schlesner, Reiner Siebert, Kostiantyn Dreval, Ryan D. Morin, Loredana Moro, Michele Pagano, Louis M. Staudt, Megan S. Lim, Kojo S.J. Elenitoba-Johnson
Journal: Cancer Discovery (2025)

Abstract The role of ubiquitin-mediated degradation mechanisms in the pathogenesis of diffuse large B cell (DLBCL) and follicular lymphoma (FL) is not completely understood. We show that conditional deletion of the E3 ubiquitin ligase Fbxo45 in germinal center B-cells results in B-cell lymphomagenesis in homozygous (100%) and heterozygous (48%) mice. Mechanistically, FBXO45 targets the RHO guanine exchange factor ARHGEF2/GEF-H1 for ubiquitin-mediated degradation. Double genetic ablation of Fbxo45 and Arhgef2 ameliorated lymphoma formation. Transgenic knock-in mice harboring a GEF-H1 mutant unable to bind FBXO45 develop B-cell lymphomas with ~50% penetrance. Genome sequencing in human lymphomas identified mutually-exclusive FBXO45 copy number losses and ARHGEF2 gains, with combined frequencies ranging from 26.32% in FL to 45.12% in DLBCL. Notably, FBXO45 silencing enhances sensitivity to MEK1/2 inhibition. These results identify FBXO45 and ARHGEF2 as a novel tumor-suppressor and oncogene pair involved in the pathogenesis of B-cell lymphomas with significant implications for targeted therapies.
Exploring Telitacicept in a patient with Pemphigus Vulgaris
Authors: Quanhong Zhang, Jun Zhang, Bintao Su, Ruili Jiang, Lang Yu, Liuqing Chen, Jinbo Chen
Journal: British Journal of Dermatology (2025)

Our case demonstrates significant improvement in autoantibody levels and clinical outcomes, suggesting telitacicept could be a alternative treatment for for mild pemphigus (PDAI ＞9) patients who is not recommended for RTX (PDAI ＜15), especially for those unresponsive to conventional treatments or with resistant scalp lesions in pemphigus.
Engineered Age‐Mimetic Breast Cancer Models Reveal Differential Drug Responses in Young and Aged Microenvironments
Authors: Jun Yang, Lauren Hawthorne, Sharon Stack, Brian Blagg, Aktar Ali, Pinar Zorlutuna
Journal: Advanced Healthcare Materials (2025)

Abstract Aging is one of the most significant risk factors for breast cancer. With the growing interest in the alterations of the aging breast tissue microenvironment, it is identified that aging is related to tumorigenesis, invasion, and drug resistance. However, current pre‐clinical disease models often neglect the impact of aging and sometimes result in worse clinical outcomes. In this study, aged animal‐generated materials are utilized to create and validate a novel age‐mimetic breast cancer model that generates an aging microenvironment for cells and alters cells toward a more invasive phenotype found in the aged environment. Furthermore, the age‐mimetic models are utilized for 3D breast cancer invasion assessment and high‐throughput screening of over 700 drugs in the FDA‐approved drug library. 36 potential effective drug targets as well as 34 potential drug targets with different drug responses in different age groups are identified, demonstrating the potential of this age‐mimetic breast cancer model for further in‐depth breast cancer studies and drug development.
Development of Functional and Hydrolytically Stable Vinyl Monomers as Methacrylate Dental Resin Restorative Alternatives
Authors: Zach Gouveia, Yoav Finer, J. Paul Santerre
Journal: Advanced Healthcare Materials (2025)

Abstract Dental resin‐based restorative (RBR) materials represent the most ubiquitous biomaterials utilized globally. Methacrylate (MA)‐ester based monomers – present in RBRs since the 1960s – experience significantly elevated rates of failure compared to previously used silver/amalgam fillings attributed to their hydrolysis reported in both simulated and in vivo environments. There is currently no alternative RBR chemistry that matches the functional and clinical workflow considerations of MA‐RBRs while addressing their limited‐service lives. The objective of this work is to utilize a systematic framework to develop alternative hydrolytically‐stable monomers (HSMs), assessing key physical properties, biostability, and cytocompatibility towards eliminating or reducing the biodegradation of RBRs. This process yielded HSMs (referreed to as 3BE, 3TE) that matched the physical properties of MA‐control materials, including viscosity, polymerization conversion, hydrophilicity, water uptake, and surface hardness ( p &gt; 0.05), while outperforming MA‐based materials in all simulated oral environments, showing improved biostability in reconstituted human saliva, simulated human salivary esterase (SHSE), bacterial culture, and acidic media ( p &lt; 0.05). Additionally, HSMs were found to be less cytotoxic than commercial MA‐monomers ( p &lt; 0.05) and unlikely to be genotoxic. Therefore, the HSMs and associated resins developed in this study have the potential to significantly improve the clinical service life of RBRs, without compromising their fundamental features.
Reservoir‐Type Subcutaneous Implantable Devices Containing Porous Rate Controlling Membranes for Sustained Delivery of Risperidone
Authors: Linlin Li, Andi Dian Permana, Juan Domínguez‐Robles, Muh Nur Amir, Habibie Habibie, Qonita Kurnia Anjani, Li Zhao, Natalia Moreno‐Castellanos, Ryan F Donnelly, Eneko Larrañeta
Journal: Advanced Healthcare Materials (2025)

Abstract Implantable drug delivery systems are crucial for achieving sustained delivery of active compounds to specific sites or systemic circulation. In this study, a novel reservoir‐type implant combining a biodegradable rate‐controlling membrane with a drug‐containing core prepared using direct compression techniques is developed. The membrane is composed of poly(caprolactone) (PCL), and risperidone (RIS) served as the model drug. Characterization of both membranes and direct compressed pellets includes hardness testing, optical coherence tomography, mercury intrusion porosimetry, and surface morphology observation. In vitro release studies of RIS reveal that higher drug loading in the pellets extended‐release duration up to 70 days when incorporated into membranes with four layers. Increasing the number of membrane layers slows the release rate further, ranging from 70 to 170 days depending on membrane thickness. Biocompatibility studies demonstrate that these implantable devices are non‐toxic and biocompatible with cells in vitro. In vivo studies conduct in male Wistar rats demonstrate sustained release of RIS, with plasma levels showing a significant increase post‐implantation at a relatively constant rate for up to 49 days. These results indicate that the developed implants have the potential to provide long‐acting drug delivery to the systemic circulation.
A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer
Authors: Amelia Acha-Sagredo, Pietro Andrei, Kalum Clayton, Emma Taggart, Carlotta Antoniotti, Chloé A Woodman, Hassnae Afrache, Constance Fourny, Maria Armero, Hafsa Kaja Moinudeen, Mary Green, Nisha Bhardwaj, Anna Mikolajczak, Maria Rodriguez-Lopez, Marg Crawford, Emma Connick, Steven Lim, Philip Hobson, Josep Linares, Ekaterina Ignatova, Diana Pelka, Elizabeth C Smyth, Nikolaos Diamantis, Dominika Sosnowska, Martina Carullo, Paolo Ciraci, Francesca Bergamo, Rossana Intini, Emma Nye, Patricia Barral, Michele Mishto, James N Arnold, Sara Lonardi, Chiara Cremolini, Elisa Fontana, Manuel Rodriguez-Justo, Francesca D Ciccarelli
Journal: Cancer Cell (2025)
Incorporating ethics into infectious disease clinical practice guidelines
Authors: Elda Righi, Dafna Yahav, Asma Nasim, Murat Akova, Aleksandra Barac, Luigia Scudeller, Blin Nagavci, Maddalena Armellini, Chiara Zanchi, Neta Shirin, Varol Tunali, José Ramón Paño-Pardo, Jesús Rodríguez-Baño, Euzebiusz Jamrozik
Journal: Clinical Microbiology and Infection (2025)
A severe case associated with mixed infections of Pasteurella multocida, Bacteroides pyogenes and Fusobacterium necrophorum due to a snow leopard bite: a case report
Authors: Huang-Liang Chen, Xiaobing Wang, Jing Li, Dongyan Fu, Qi-Tao Zhang, Wen-Long Zhao, Yi-Xin Ma, Rui Qi
Journal: Clinical Microbiology and Infection (2025)
Anthropometric Trajectories in Children Prior to Development of Inflammatory Bowel Disease
Authors: Maiara Brusco De Freitas, Gry Juul Poulsen, Tine Jess
Journal: JAMA Network Open (2025)

Importance Poor nutrition and growth in childhood have short-term and long-term consequences, so understanding the timing of the onset of an impaired nutritional status is crucial for diagnosing and treating inflammatory bowel disease (IBD) at its earliest stage. Objective To assess anthropometric trajectories before a pediatric diagnosis of IBD and growth recovery after diagnosis. Design, Setting, and Participants This population-based cohort study included children born in Denmark from January 1, 1997, through December 31, 2015, with weight and length or height measurements at birth and at least 1 length or height and weight measurement at school age based on the Danish Medical Birth Register and the Danish National Child Health Register. Within this population, all individuals diagnosed with IBD at ages 5 to 17 years, according to the Danish National Patient Register, were identified. Data were analyzed from October 13, 2023, to April 17, 2024. Exposure A pediatric diagnosis of IBD compared with the corresponding population without the disease. Main Outcomes and Measures The outcome measures were z scores for length or height, weight, and body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]) before and after pediatric IBD diagnosis compared with reference and sibling populations. Results The final study population included 916 133 individuals (51.2% male) with a median of 3 pairs of length or height and weight measurements collected (IQR, 2-6 pairs). Of those, 1522 (median age, 14.3 years [IQR, 11.8-16.3 years]; 763 female [50.1%]) were diagnosed with IBD (851 [55.9%] with Crohn disease [CD] and 671 [44.1%] with ulcerative colitis [UC]). Compared with children without IBD, individuals with a later diagnosis of CD had declining anthropometric measures 3 years (weight: mean, −0.12 g [95% CI, −0.20 to −0.03 g]; BMI: mean, −0.13 [95% CI, −0.21 to −0.04]) and 1 year (length or height: mean, −0.20 cm [95% CI, −0.29 to −0.10 cm]) prior to diagnosis, whereas this was observed 1 year prior to a diagnosis of UC for weight (mean, −0.12 g [95% CI, −0.22 to −0.02 g]) and BMI (mean, −0.13 [95% CI, −0.23 to −0.03]). Deviating anthropometric patterns persisted after diagnosis, with the slowest recovery observed in children with CD. Conclusions and Relevance The findings of this large-scale population-based cohort study of anthropometrics in children suggest impaired nutritional status as assessed by weight up to 3 years and by length or height 1 year before a diagnosis of CD and by weight up to 1 year before a diagnosis of UC. These findings emphasize that the onset of pediatric IBD may occur years prior to diagnosis, that growth recovery may first occur after diagnosis and treatment, and that frequent nutritional screenings may help ensure a healthy transition to adulthood.
"Effectiveness and tolerability of intravenous fosfomycin in treating complicated urinary tract infections caused by Escherichia coli: A prospective cohort study from the FOSFO-MIC Project"
Authors: Elisa Moreno-Mellado, Abdullah Tarik Aslan, Murat Akova, Eva León, Nicolás Merchante, David Vinuesa, Encarnación Moral-Escudero, Svetlana Sadyrbaeva-Dolgova, Salvador López-Cárdenas, Ángela Cano-Yuste, Matteo Rinaldi, María Núñez-Núñez, Maddalena Giannella, Jesús Sojo-Dorado, Ana Cristina Antolí-Royo, Natalia Chacón, Vicente Merino-Bohórquez, Inés Portillo, Jesús Rodríguez-Baño, Fernando Docobo-Pérez, Belén Gutiérrez-Gutiérrez
Journal: Clinical Microbiology and Infection (2025)
Dosing and route of administration of clindamycin given in combination with rifampicin
Authors: Sophie Magréault, Racym Berrah, Younes Kerroumi, Léo Mimram, Dominique Salmon, Tiphaine Goulenok, Andrea de la Selle, Agnès Lefort, Simon Marmor, Najoua Hel Helali, Valérie Zeller, Vincent Jullien
Journal: Clinical Microbiology and Infection (2025)
ENHANCED RESTORATION OF VISUAL CODE AFTER TARGETING ON BIPOLAR CELLS COMPARED TO RETINAL GANGLION CELLS WITH OPTOGENETIC THERAPY
Authors: Jessica Rodgers, Steven Hughes, Aghileh S Ebrahimi, Annette E Allen, Riccardo Storchi, Moritz Lindner, Stuart N Peirson, Tudor C Badea, Mark W Hankins, Robert J Lucas
Journal: Molecular Therapy (2025)
Estimated Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease in US Adults, 2020 to 2050
Authors: Phuc Le, Moosa Tatar, Srinivasan Dasarathy, Naim Alkhouri, William H. Herman, Glen B. Taksler, Abhishek Deshpande, Wen Ye, Olajide A. Adekunle, Arthur McCullough, Michael B. Rothberg
Journal: JAMA Network Open (2025)

Importance Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease and is projected to become the leading indication for liver transplant (LT) in the US. Understanding its clinical burden can help to identify opportunities for prevention and treatment. Objective To project the burden of MASLD in US adults from 2020 to 2050. Design, Setting, and Participants This decision analytical modeling study used an agent-based state transition model that simulates the natural history of MASLD progression among adults 18 years of age or older. Primary data sources for model inputs were the published literature. Exposure Natural history of MASLD. Main Outcomes and Measures Cases of MASLD, metabolic dysfunction–associated steatohepatitis (MASH), fibrosis, hepatocellular carcinoma (HCC), LT, and liver-related death. Results The model simulated 2 821 624 individuals (mean age. 35.8 years; 50.9% female). The model predicted a steady increase in the prevalence of MASLD from 33.7% (86.3 million people) in 2020 to 41.4% (121.9 million people) by 2050. Cases of MASH would increase from 14.9 million (5.8% of US adults) in 2020 to 23.2 million (7.9% of US adults) by 2050. The number of cases of MASH and clinically significant fibrosis (ie, F≥F2, centrilobular and periportal fibrosis or more severe disease) were estimated to increase from 6.7 million to 11.7 million. By 2046 to 2050, MASLD would cause 22 440 new cases of HCC and 6720 new cases of LT per year compared with 11 483 new cases of HCC and 1717 new cases of LT in 2020 to 2025. Liver-related mortality was estimated to increase from 30 500 deaths (1.0% of all-cause deaths in adults) in 2020 to 95 300 deaths (2.4%) in 2050. Conclusions and Relevance In this decision analytical modeling study, the model forecast a substantial increase in clinical burden of MASLD over the next 3 decades in the absence of effective treatments. These results suggest that health systems should plan for large increases in the number of HCC cases and in the need for LT.